FDA Approves initiation of IGC’s cannabinoid trial on Alzheimer’s patients
POTOMAC: India Globalization Capital announced that on July 30, 2020, the U.S. Food and Drug Administration (FDA) notified IGC that it has authorized the Company to initiate a Phase 1 human trial study for the Company’s investigational cannabinoid formulation for the treatment of patients suffering from mild to severe dementia due to Alzheimer’s disease. After…